Companies: 10,795·Total market cap: $144.5T
BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

BMRNNASDAQHealthcare● Active
$56.77
+$0.30(+0.53%)
Market Cap$11.0B
P/E Ratio
52W High$66.28
52W Low$49.26
Overview

BioMarin Pharmaceutical Inc. (BMRN) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BMRN · as of Jun 8, 2026

Key Statistics

EPS (TTM)$1.40bmrn eps ttm · bmrn earnings per shareEarnings history
PE Ratio (TTM)40.5×bmrn pe ratio ttm · bmrn price to earningsPE Ratio deep dive
Revenue (TTM)$3.2Bbmrn revenue ttm · bmrn annual revenueFull revenue history
Dividend YieldNo Dividenddoes bmrn pay dividends · bmrn dividend yieldDividend history
Shares Outstanding191.8Mbmrn shares outstanding · bmrn floatShares outstanding history
Next EarningsAug 3, 2026Est.bmrn earnings date · bmrn next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$3.22B▲ +12.87% YoY
202320242025
biomarin pharmaceutical inc. revenue · bmrn revenue 2025
FY 2025Net Income$348.9M▼ 18.26% YoY
202320242025
biomarin pharmaceutical inc. net income · bmrn profit 2025
FY 2025EPS$1.82▼ 19.11% YoY
202320242025
bmrn eps · biomarin pharmaceutical inc. earnings per share 2025
TTM:Revenue: $3.24BNet Income: $268.7MEPS: $1.40View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy41 analystsis bmrn a buy · bmrn analyst rating
Strong Buy
0
Buy
28
Hold
13
Sell
0
Strong Sell
0
12-Month Price Target
$50.00Low
$56.77Current
$89.93Avg Target58.41% upside
$120.00High
bmrn price target · bmrn 12 month forecast

Total: 41 · Buy rate: 68.3%

The BMRN analyst consensus is Buy, based on ratings from 41 Wall Street analysts over the past 3 months. The average 12-month price target is $89.93, representing +58.41% upside from the current price of $56.77.

Stock Performance

Full History
1D+0.53%
1W+6.47%
1M+5.01%
3M-7.12%
YTD-4.48%
1Y-0.19%
5Y-27.92%

About BioMarin Pharmaceutical Inc.

CEOAlexander Hardy
IPO DateJul 26, 1999
Employees3,040
CountryUS

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme…

what is biomarin pharmaceutical inc. · bmrn stock overview · biomarin pharmaceutical inc. company profile · who is biomarin pharmaceutical inc. ceo · bmrn NASDAQ · biomarin pharmaceutical inc. headquarters · biomarin pharmaceutical inc. business segments

About Stock Overview & Key Data

BioMarin Pharmaceutical Inc. (BMRN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 26, 1999. As of the latest trading session, BMRN stock price is $56.77, with a market capitalization of $11.0B. The stock has returned -0.19% over the past 12 months and -4.48% year-to-date.

According to 41 Wall Street analysts, the consensus rating for BioMarin Pharmaceutical Inc. stock is Buy, with an average 12-month price target of $89.93. In fiscal year 2025, BioMarin Pharmaceutical Inc. reported revenue of $3.2B and net income of $348.9M. For detailed data — including BioMarin Pharmaceutical Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, BioMarin Pharmaceutical Inc. (BMRN) stock price is $56.77. The stock is traded on NASDAQ under the ticker symbol BMRN. The 52-week range is $49.26 – $66.28.

BMRN stock priceBMRN quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice